Introduction: Hereditary transthyretin amyloidosis polyneuropathy (ATTRv-PN) pre-symptomatic carriers often show preclinical abnormalities at small fibre related diagnostic tests. However, no validated biomarker is currently available to use for pre-symptomatic carriers' follow-up, thus helping therapeutic decision making. Our study aimed at assessing nerve conduction study (NCS), quantitative sensory testing (QST), and skin biopsy parameters in a large cohort of late-onset ATTRv pre-symptomatic carriers, and to evaluate whether they correlated with predicted age of disease onset (PADO). Methods: Late-onset ATTRv pre-symptomatic carriers were consecutively enrolled and underwent NCS, QST, and skin biopsy with intraepidermal nerve fibre density (IENFD) evaluation from a distal and a proximal site. Douleur Neuropathique-4 (DN4) and Small Fiber Neuropathy-Symptoms Inventory (SFN-SIQ) were used to assess painful and small fibre neuropathy related symptoms. PADO and time-to-PADO (delta-PADO) were estimated for each carrier, and correlations with diagnostic test measures were analysed. Results: Forty pre-symptomatic ATTRv subjects were enrolled. Twenty carriers (50%) had distal IENFD reduction, with a non-length dependent distribution in 73% of cases. Eleven subjects (27.5%) had cold and/or warm detection threshold (CDT and/or WDT) abnormalities at QST. Delta-PADO positively correlated with sural sensory nerve action potential (SNAP) amplitude (r = 0.416, p = 0.004), and z-values of QST parameters like CDT (r = 0.314, p = 0.028), WDT (r = -0.294, p = 0.034), and mechanical detection threshold (MDT) (r = -0.382, p = 0.012). Simple linear regression models showed a linear relation between delta-PADO and sural SAP, CDT, and MDT. Conclusions: Our findings confirm that IENFD reduction and QST abnormalities may occur early in ATTRv pre-symptomatic carriers, often with a non-length dependent pattern. However, only sural SAP amplitude and QST parameters correlated with delta-PADO, suggesting that serial combined QST and NCS evaluation could be useful in ATTRv pre-symptomatic carriers' follow-up. This article is protected by copyright. All rights reserved.
Quantitative sensory testing and skin biopsy findings in late‐onset ATTRv pre‐symptomatic carriers: relationships with predicted time of disease onset (PADO) / Leonardi, Luca; Costanzo, Rocco; Forcina, Francesca; Morino, Stefania; Antonini, Giovanni; Salvetti, Marco; Luigetti, Marco; Romano, Angela; Primiano, Guido; Guglielmino, Valeria; Fionda, Laura; Garibaldi, Matteo; Lauletta, Antonio; Rossini, Elena; Tufano, Laura; Ceccanti, Marco; Esposito, Nicoletta; Falco, Pietro; DI PIETRO, Giuseppe; Truini, Andrea; Galosi, Eleonora. - In: JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. - ISSN 1085-9489. - (2023). [10.1111/jns.12586]
Quantitative sensory testing and skin biopsy findings in late‐onset ATTRv pre‐symptomatic carriers: relationships with predicted time of disease onset (PADO)
Luca Leonardi
Primo
;Rocco Costanzo;Francesca Forcina;Stefania Morino;Giovanni Antonini;Marco Salvetti;Laura Fionda;Matteo Garibaldi;Antonio Lauletta;Elena Rossini;Laura Tufano;Marco Ceccanti;Nicoletta Esposito;Pietro Falco;Giuseppe di Pietro;Andrea Truini;Eleonora GalosiUltimo
2023
Abstract
Introduction: Hereditary transthyretin amyloidosis polyneuropathy (ATTRv-PN) pre-symptomatic carriers often show preclinical abnormalities at small fibre related diagnostic tests. However, no validated biomarker is currently available to use for pre-symptomatic carriers' follow-up, thus helping therapeutic decision making. Our study aimed at assessing nerve conduction study (NCS), quantitative sensory testing (QST), and skin biopsy parameters in a large cohort of late-onset ATTRv pre-symptomatic carriers, and to evaluate whether they correlated with predicted age of disease onset (PADO). Methods: Late-onset ATTRv pre-symptomatic carriers were consecutively enrolled and underwent NCS, QST, and skin biopsy with intraepidermal nerve fibre density (IENFD) evaluation from a distal and a proximal site. Douleur Neuropathique-4 (DN4) and Small Fiber Neuropathy-Symptoms Inventory (SFN-SIQ) were used to assess painful and small fibre neuropathy related symptoms. PADO and time-to-PADO (delta-PADO) were estimated for each carrier, and correlations with diagnostic test measures were analysed. Results: Forty pre-symptomatic ATTRv subjects were enrolled. Twenty carriers (50%) had distal IENFD reduction, with a non-length dependent distribution in 73% of cases. Eleven subjects (27.5%) had cold and/or warm detection threshold (CDT and/or WDT) abnormalities at QST. Delta-PADO positively correlated with sural sensory nerve action potential (SNAP) amplitude (r = 0.416, p = 0.004), and z-values of QST parameters like CDT (r = 0.314, p = 0.028), WDT (r = -0.294, p = 0.034), and mechanical detection threshold (MDT) (r = -0.382, p = 0.012). Simple linear regression models showed a linear relation between delta-PADO and sural SAP, CDT, and MDT. Conclusions: Our findings confirm that IENFD reduction and QST abnormalities may occur early in ATTRv pre-symptomatic carriers, often with a non-length dependent pattern. However, only sural SAP amplitude and QST parameters correlated with delta-PADO, suggesting that serial combined QST and NCS evaluation could be useful in ATTRv pre-symptomatic carriers' follow-up. This article is protected by copyright. All rights reserved.File | Dimensione | Formato | |
---|---|---|---|
Leonardi_Quantitative-sensory-testing_2023.pdf
Open Access dal 03/08/2024
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
2.75 MB
Formato
Adobe PDF
|
2.75 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.